Replimune Group Inc. (REPL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Replimune Group Inc. (REPL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.49

-0.40 (-3.67%)

At close: Jan 14, 2025, 3:59 PM

10.55

0.57%

After-hours Jan 14, 2025, 05:01 PM EST

undefined% (undefined)

Bid	5.06
Market Cap	790.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.04
PE Ratio (ttm)	-3.45
Forward PE	n/a
Analyst	Buy

Ask	11.48
Volume	784,395
Avg. Volume (20D)	792,940
Open	11.05
Previous Close	10.89
Day's Range	10.12 - 11.20
52-Week Range	4.92 - 17.00
Beta	undefined

About REPL

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Pha...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 20, 2018

Employees 331

Stock Exchange NASDAQ

Ticker Symbol REPL

Website https://www.replimune.com

Analyst Forecast

According to 6 analyst ratings, the average rating for REPL stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 62.06% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

+8.45%

Replimune Group shares are trading higher. The com... Unlock content with Pro Subscription

1 month ago · Source

+35.11%

Replimune Group shares are trading higher after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.

News

1 month ago · seekingalpha.com

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is under...

1 month ago · zacks.com

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.